Immunology Sponsored by Beckman Coulter
Early trials show potential of Pfizer COVID-19 vaccine
Pharmaceutical giant Pfizer is making progress on BNT162b1, a COVID-19 vaccine candidate that is undergoing development and for which the U.S. government has secured access to 300 million doses in 2021. The results of the phase I/II clinical trials were published in Nature on August 12.  Discuss
Sharing is caring: Why COVID-19 vaccine manufacturers must collaborate
Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming months. Such collaboration could change the way that innovation and competition are viewed in the biopharmaceutical industry, according to a policy forum published in Science on August 13.  Discuss
SARS-CoV-2 causes immune paralysis in severe cases of COVID-19
The SARS-CoV-2 virus can cause the paralysis of key immune cells as the COVID-19 disease progresses, and this immune paralysis can be the difference between severe and mild cases of COVID-19, according to a study published in Science on August 11.  Discuss
Biosimulation can mitigate risk of COVID-19 drug development
Drug development can be an expensive and tedious process. Add in the urgency of the COVID-19 pandemic, and you have a recipe for frustration. Biosimulation -- using computers to simulate drug response in humans -- can help accelerate the process, which Certara hopes to achieve with a newly launched platform targeted at COVID-19 vaccine development.  Discuss
COVID-19 vaccine based on peptide nanofibers shows promise
A new technology platform using self-assembling peptide nanofibers tagged with antibodies can be an effective SARS-CoV-2 vaccine, according to a proof-of-concept study published in Science Advances on August 7.  Discuss
Gum disease may affect COVID-19 severity
Patients with inflammation caused by periodontitis may experience more severe COVID-19 complications, according to an article published online July 30 in the Journal of the California Dental Association.  Discuss
Microbes shape antibodies prior to infection
Genetic analysis of antibodies reveals how microbes in the intestines impact overall B-cell populations and humoral responses to pathogens. The research was published in Nature on August 5.  Discuss
New COVID-19 vaccine candidate leverages earlier research
Could vaccine platforms developed for previous coronaviruses be converted to address the current COVID-19 pandemic? An August 5 report in Nature described how researchers leveraged previous vaccine research to develop mRNA-1273, a new SARS-CoV-2 vaccine candidate.  Discuss
Study analyzes how SARS-CoV-2 undermines immune defenses
A new research study used whole-genome sequencing to analyze the genetic profile of patients with the SARS-CoV-2 virus to gain more insight into how it turns the body's own immune system against itself. The findings could help researchers develop drugs to target the virus, according to an August 3 report in Nature Medicine.  Discuss
Researchers develop mouse model of COVID-19 infection
Researchers have generated a strain of SARS-CoV-2 that can infect mice and used it to produce a new mouse model of infection to help facilitate testing of COVID-19 vaccine candidates and therapies. The research article was published in Science on July 30.  Discuss
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
ASGCT 2020 Policy Summit
September 23-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter